心肌缺血综合征:一个新的命名法来协调不断变化的国际临床实践指南
William E Boden1, Raffaele De Caterina2, Juan Carlos Kaski3
1VA Boston Healthcare System, Boston University School of Medicine, 150 S. Huntington Avenue, Boston, MA 02130, USA.
European heart journal
|August 30, 2024
概括
心肌缺血的新分类旨在统一术语,包括阻塞性和非阻塞性原因. 这旨在改善慢性冠状动脉综合征和急性心肌梗塞等疾病的诊断和治疗.
科学领域:
- 心脏病学 心脏病学
- 医学术语 医学术语 医学术语
- 缺血性心脏病 缺血性心脏病
背景情况:
- 目前慢性心肌缺血的分类使用矛盾的术语,如"稳定冠状动脉疾病" (CAD) 和"慢性冠状动脉综合征" (CCS).
- 竞争的指导方针 (欧洲与美国) 引入了不同的术语,导致混乱.
- 现有的术语如"冠状动脉"和"疾病"往往只关注阻塞性CAD,不包括其他机制.
研究的目的:
- 为心肌缺血症提出一个新的,包容性的二进制分类.
- 在国际准则中统一不同的命名法.
- 促进对痛和心肌缺血的阻塞性和非阻塞性原因的概念清晰度.
主要方法:
- 提出了二元分类:"急性心肌缺血综合征"和"非急性心肌缺血综合征".
- 包括阻塞性表心和非阻塞性致病机制 (例如,微血管功能障碍,血管缩性疾病).
- 保持了急性冠状动脉综合征 (ACS) 和心肌梗塞 (MI) 亚型的既定类别.
主要成果:
- 拟议的分类涵盖了更广泛的致病遗传机制.
- 它包括诸如缺血和心脏病发作与非阻塞性冠状动脉等疾病.
- 新的命名法协调了心肌缺血的不同病理生理学原因.
结论:
- 拟议的分类为心肌缺血症提供了一个更全面的命名体系.
- 它更好地协调和统一诊断和治疗方法.
- 这应该导致更精细的治疗方法,以向Angina,缺血和心脏病发作的各种病理学沉物.
相关概念视频
01:17Ischemic Heart Disease: Overview
1.2K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.2K
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.1K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.1K
01:16Antianginal Drugs: Nitrates and β-Blockers
547
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
547
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
464
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
464
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
404
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404